Type 2 Diabetes Clinical Trial
Official title:
Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes
Verified date | May 2019 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to try and achieve similar glycemic control in general non-Intensive Care Unit (non-ICU) patients with Type 2 Diabetes with exenatide alone or in combination with basal insulin as compared to treatment with basal bolus insulin alone. The association between hyperglycemia and poor clinical outcomes in patients with diabetes is well established. Previous studies have shown that basal bolus insulin regimens improve glycemic control and reduce the rate of hospital complications compared to sliding scale regular insulin (SSRI) therapy, but has a significant risk of hypoglycemia. The investigators will compare the efficacy and safety of exenatide alone or in combination with basal insulin to control high blood glucose levels resulting in a lower risk of hypoglycemia.
Status | Completed |
Enrollment | 150 |
Est. completion date | March 2018 |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. A known history of Type 2 Diabetes receiving either diet alone or oral antidiabetic drugs (OAD) including insulin secretagogues, pioglitazone, DPP4 inhibitors, or metformin as monotherapy or in combination therapy, or low-dose insulin at <0.5 unit/kg/day. 2. Males or females between the ages of 18 and 80 years discharged after hospital admission from general medicine and surgery services (non-Intensive Care Unit setting). 3. Subjects with an admission / randomization BG < 400 mg/dL without laboratory evidence of diabetic ketoacidosis (serum bicarbonate < 18 mEq/L or positive serum or urinary ketones). 4. Admission HbA1c between 7% and 10% 5. BMI range: > 25 Kg/m^2 and < 45 Kg/m^2 Exclusion Criteria: 1. Age < 18 or > 80 years 2. Subjects with increased blood glucose (BG) concentration, but without a history of diabetes (stress hyperglycemia) 3. Subjects with a history of type 1 diabetes (suggested by BMI < 25 Kg/m^2 requiring insulin therapy or with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state, or ketonuria). 4. Treatment with high-dose (>0.5 unit/kg/day) insulin or with GLP-1 RA during the past 3 months prior to admission. 5. Patients that required ICU care during the hospital admission. 6. Recurrent severe hypoglycemia or hypoglycemic unawareness. 7. Subjects with gastrointestinal obstruction, gastroparesis, history of pancreatitis or those expected to require gastrointestinal suction. 8. Patients with clinically relevant pancreatic or gallbladder disease. 9. Patients with unstable or rapidly progressing renal disease or severe renal impairment (creatinine clearance < 30 ml/min) 10. Patients with clinically significant hepatic disease (cirrhosis, jaundice, end-stage liver disease), 11. History of hypersensitivity to exenatide 12. Treatment with oral or injectable corticosteroid (equal to a prednisone dose >5 mg/day), parenteral nutrition and immunosuppressive treatment. 13. Patients with history of heavy alcohol use (female > 2 drinks per day, male > 3 drinks per day) or drug abuse within 3 months prior to admission. 14. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. 15. Female subjects who are pregnant or breast feeding at time of enrollment into the study. |
Country | Name | City | State |
---|---|---|---|
United States | Emory University Hospital | Atlanta | Georgia |
United States | Grady Memorial Hospital | Atlanta | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Daily Blood Glucose Concentration Inpatient | The levels of blood glucose (BG) will be measured before each meal and at bedtime using a glucose meter. Blood glucose will be measured at baseline and during the hospital stay (up to 10 days). | Duration of hospital stay, an expected average of 10 days. | |
Primary | Change in HbA1c Concentration Inpatient | The difference in the levels of HbA1c at discharge and at 12 weeks from discharge will be measured. The A1C test result is reported as a percentage. The higher the percentage, the higher a person's blood glucose levels have been. A normal A1C level is below 5.7 percent. | 12 weeks from discharge. | |
Secondary | Mean Fasting Blood Glucose Levels Inpatient | The blood glucose levels prior to the patient's first meal of the day will be assessed using a glucose meter. | Duration of hospital stay, an expected average of 10 days. | |
Secondary | Mean Premeal Blood Glucose Levels Inpatient | The blood glucose levels prior to each meal will using a glucose meter. | Duration of hospital stay, an expected average of 10 days | |
Secondary | Incidence of Hypoglycemic Events Inpatient | The number of patients with hypoglycemia (blood glucose levels < 70 mg/dL) will be recorded. | Duration of hospital stay, an expected average of 10 days | |
Secondary | Incidence of Hyperglycemic Events Inpatient | Percent of readings with hyperglycemia (blood glucose levels > 240 mg/dL) | Duration of hospital stay, an expected average of 10 days | |
Secondary | Total Daily Dose of Insulin Inpatient | The total daily dose of insulin needed for glycemic control from baseline through the patient's hospital stay will be recorded. | Duration of hospital stay, an expected average of 10 days | |
Secondary | Average Number of Days of Hospital Stay | The average number of days in the hospital for subjects will be calculated. | Duration of hospital stay, an expected average of 10 days | |
Secondary | Incidence of the Need for ICU Care Inpatient | The total number of patients who require transfer to the ICU will be recorded. | Duration of hospital stay, an expected average of 10 days | |
Secondary | Hospital Mortality | The total number of subject deaths during hospital stay will be recorded. | Duration of hospital stay, an expected average of 10 days | |
Secondary | Hospital Complications | The total number of subjects who experience hospital complications like nosocomial pneumonia, bacteremia, respiratory failure, acute renal failure, and wound infections (surgery patients) will be recorded. Nosocomial infections will be diagnosed based on standardized Centers for Disease Control (CDC) criteria. | Duration of hospital stay, an expected average of 10 days | |
Secondary | Incidence of Acute Kidney Injury Inpatient | The number of patients who experience acute kidney injury diagnosed by an increment in serum creatinine >0.5 mg/dL from admission value or 50% of baseline value will be recorded. | Duration of hospital stay, an expected average of 10 days | |
Secondary | Incidence of Gastrointestinal Adverse Events Inpatient | The number of subjects who experience gastrointestinal side effects including nausea, vomiting and diarrhea will be recorded. | Duration of hospital stay, an expected average of 10 days | |
Secondary | Number of Patients With Severe Hypoglycemic Events Inpatient | Occurrences of hypoglycemia (blood glucose levels < 40 mg/dL) will be recorded. | Duration of hospital stay, an expected average of 10 days | |
Secondary | Incidence of Hospital Readmissions | The number of patients who require readmission to the hospital from the time of discharge to 12 weeks after discharge will be recorded. | 12 weeks after discharge | |
Secondary | Mean Fasting Blood Glucose Levels During Outpatient Period | Fasting Blood Glucose Levels were measured using blood test | 12 weeks after discharge | |
Secondary | Mean Daily Blood Glucose Concentration During Outpatient Period | Mean Daily Blood Glucose Concentration will be calculated and recorded. | 12 weeks after discharge | |
Secondary | The Number of Patients With Hypoglycemia Outpatient | Occurrence of hypoglycemia (blood glucose levels < 70 mg) will be identified by blood test | 12 weeks after discharge | |
Secondary | Number of Patients With Severe Hypoglycemic Events | Occurrences of hypoglycemia (blood glucose levels < 40 mg/dL) will be detected by blood test | 12 weeks after discharge | |
Secondary | Change in Body Weight | The change in Body Weight from discharge to 12 weeks after discharge will be recorded | Time of discharge, 12 weeks after discharge | |
Secondary | Change in Body Mass Index | The change in BMI from discharge to 12 weeks after discharge will be calculated | Discharge (after day 10 or hospital stay), 12 weeks after discharge 12 weeks after discharge | |
Secondary | Number of Patients Who Had Emergency Room Visits | The number of patients who had emergency room visits from the time of discharge to 12 weeks after discharge will be recorded. | 12 weeks after discharge | |
Secondary | Number of Hospital Readmissions | Number of hospital readmissions during 12 weeks after discharge will be recorded | 12 weeks after discharge | |
Secondary | Number of Acute Kidney Injury Events | Number of Acute Kidney Injury events will be recorded | 12 weeks from discharge. | |
Secondary | Number of Severe Gastrointestinal Adverse Events | Number of Severe (require hospitalization) Gastrointestinal Adverse Events | 12 weeks from discharge. | |
Secondary | Change in Systolic Blood Pressure | Change in Systolic Blood Pressure from the time of discharge to 12 weeks after discharge will be recorded | Discharge (after day 10 or hospital stay), 12 weeks after discharge | |
Secondary | Change in Heart Rate | Change in heart rate from the time of discharge to 12 weeks after discharge will be recorded | Discharge (after day 10 or hospital stay), 12 weeks after discharge | |
Secondary | Efficacy, Measured by HbA1c Levels and no Weight Gain | Number of patients who have an HbA1c <7.0% and no weight gain at 12 weeks from discharge will be recorded. | 12 weeks from discharge. | |
Secondary | Efficacy, Measured by HbA1c Levels and no Hypoglycemia | Number of patients who have an HbA1c <7.0% and no hypoglycemia at 12 weeks from discharge will be recorded. | 12 weeks from discharge. | |
Secondary | Change in Diastolic Blood Pressure | Change in Diastolic Blood Pressure from the time of discharge to 12 weeks after discharge will be recorded | Discharge (after day 10 or hospital stay), 12 weeks after discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |